Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
Top Cited Papers
Open Access
- 30 September 2017
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 18 (10), 1373-1385
- https://doi.org/10.1016/S1470-2045(17)30517-X
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Reply to M.S. LesniakJournal of Clinical Oncology, 2011
- Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastomaNeuro-Oncology, 2010
- Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed GlioblastomaJournal of Clinical Oncology, 2010
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working GroupJournal of Clinical Oncology, 2010
- Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapyExpert Opinion on Biological Therapy, 2007
- Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized TrialJournal of Clinical Oncology, 2006
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaThe New England Journal of Medicine, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005
- Investigation of a synthetic peptide as immunogen for a variant epidermal growth factor receptor associated with gliomasJournal of Neuroimmunology, 1993
- Recursive Partitioning Analysis of Prognostic Factors in Three Radiation Therapy Oncology Group Malignant Glioma TrialsJNCI Journal of the National Cancer Institute, 1993